References
- De Wees W. Editorial comment. Philadelphia Journal of Medical and Physical Sciences 1825:207.
- Doubleday E. Case of uterine haemorrhage successfully treated by the operation of transfusion. Philadelphia Journal of Medical Physics 1825;54:380–6.
- Chapman JF, Elliott C, Knowles SM, et al. Guidelines for compatibility procedures in blood transfusion laboratories: British Committee for Standards in Haematology. Transfus Med 2004;14:50–73.
- AABB Standards Program Committee. Standards for immunohematology reference laboratories. 9th ed. Arlington, VA: AABB, 2016.
- U.S. Food and Drug Administration. Transfusion associated fatalities 2010–2014. Available from www.fda.gov. Accessed May 2017
- Bolton-Maggs PHB, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress in improving transfusion safety. Br J Haematol 2013;1:1–12.
- Moncharmont P, Barday G, Py J-Y, et al. Acquired red blood cell alloantibodies in transfused patients of 80 years or over: a 2008–2013 national haemovigilance survey. Blood Transfus 2017;15:254–8.
- Leger R. In vitro cellular assays and other approaches used to predict the clinical significance of red cell alloantibodies: a review. Immunohematology 2002;18:65–70.
- Daniels G, Poole J, De Silva M, et al. The clinical significance of blood group antibodies. Transfus Med 2002;12:287–95.
- Poole J, Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 2007;21:58–71.
- Whitaker BI, Strong DM, Gandhi MJ, Petrisli E. Hemovigilance and the Notify Library. Immunohematology 2017;33:159–64.
- Garratty G. The James Blundell Award Lecture 2007: Do we really understand immune red cell destruction. Transfus Med 2008:18;321–34.
- Zupanska B, Thompson E, Brojer E, Merry AH. Phagocytosis of erythrocytes sensitized with known amounts of IgG1 and IgG3 anti-Rh antibodies. Vox Sang 1987;53:96–101.
- Garratty G, Nance SJ. Correlation between in vivo hemolysis and the amount of red cell-bound IgG measured by flow cytometry. Transfusion 1990:30;617–21.
- Garratty G. Effect of cell-bound proteins on the in vivo survival of circulating blood cells. Gerontology 1991:37;68–94.
- Hadley AG. A comparison of in vitro tests for predicting the severity of hemolytic disease of the fetus and newborn. Vox Sang 1998;74:375–83.
- Hadley AG. The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies. Clin Lab Haematol 1988;10:377–84.
- Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus Med Rev 1990;4:297–312.
- Nance S, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449–52.
- Schanfield M, Stevens JO, Bauman D. The detection of clinically significant erythrocyte alloantibodies using human mononuclear phagocyte assay. Transfusion 1981;21:571–6.
- Zupanska B, Brijer E, McIntosh J, et al. Correlation of monocyte monolayer assay results, number of erythrocyte-bound IgG molecules, and IgG subclass composition in the study of red cell alloantibodies other than D. Vox Sang 1990;58:276–80.
- Mollison PL. Blood-group antibodies and red-cell destruction— II. Br Med J 1959:2:1123–30.
- Postoway N, Nance S, O’Neill P, Garratty G. Comparison of a practical differential agglutination procedure to flow cytometry in following the survival of transfused red cells. Transfusion 1985;25:453.
- Nance S, Scharberg EA, Thornton N, Yahalom V, Sareneva I, Lomas-Francis C. International rare donor panels: a review. Vox Sang 2016;110:209–18.